UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Psoriatic Arthritis

The New England journal of medicine, 2017-03, Vol.376 (10), p.957-970

2017

Volltextzugriff (PDF)

Axial spondyloarthritis: new advances in diagnosis and management

BMJ (Online), 2021-01, Vol.372, p.m4447

2021

Volltextzugriff (PDF)

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

The Lancet (British edition), 2023-01, Vol.401 (10370), p.25-37

2023

Volltextzugriff (PDF)

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial

Arthritis & rheumatology (Hoboken, N.J.), 2019-07, Vol.71 (7), p.1112-1124

2019

Volltextzugriff (PDF)

In Memoriam: Evan Calkins, MD, 1920–2020

Arthritis & rheumatology (Hoboken, N.J.), 2020-08, Vol.72 (8), p.1252-1253

Ritchlin, Christopher T.

2020

Volltextzugriff (PDF)

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet (British edition), 2015-09, Vol.386 (9999), p.1137-1146

2015

Volltextzugriff (PDF)

Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis

Expert opinion on biological therapy, 2017-01, Vol.17 (1), p.119-128

2017

Volltextzugriff (PDF)

Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey

Rheumatology and therapy., 2016-06, Vol.3 (1), p.91-102

2016

Volltextzugriff (PDF)

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

The New England journal of medicine, 2014-06, Vol.370 (24), p.2295-2306

2014

Volltextzugriff (PDF)

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

Arthritis research & therapy, 2018-03, Vol.20 (1), p.47-11, Article 47

2018

Volltextzugriff (PDF)

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

The Lancet (British edition), 2020-04, Vol.395 (10230), p.1115-1125

2020

Volltextzugriff (PDF)

DC-STAMP: A Key Regulator in Osteoclast Differentiation

Journal of cellular physiology, 2016-11, Vol.231 (11), p.2402-2407

2016

Volltextzugriff (PDF)

Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions

Calcified tissue international, 2018-05, Vol.102 (5), p.559-574

2018

Volltextzugriff (PDF)

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Journal of rheumatology, 2018-10, Vol.45 (10), p.1389-1396

2018

Volltextzugriff (PDF)

New therapies for psoriasis and psoriatic arthritis

Current opinion in rheumatology, 2016-05, Vol.28 (3), p.204-210

2016

Volltextzugriff (PDF)

Targeting the interleukin-23/17 axis in axial spondyloarthritis

Current opinion in rheumatology, 2016-07, Vol.28 (4), p.359-367

2016

Volltextzugriff (PDF)

Etiology and Pathogenesis of Psoriatic Arthritis

Rheumatic diseases clinics of North America, 2015-11, Vol.41 (4), p.643-663

2015

Volltextzugriff (PDF)

Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting

Journal of rheumatology, 2021-02, p.jrheum.201669

2021

Volltextzugriff (PDF)

High-throughput micro-CT analysis identifies sex-dependent biomarkers of erosive arthritis in TNF-Tg mice and differential response to anti-TNF therapy

PloS one, 2024-07, Vol.19 (7), p.e0305623

2024

Volltextzugriff (PDF)

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

The Lancet (British edition), 2023-01, Vol.401 (10370), p.38-48

2023

Volltextzugriff (PDF)

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

The Lancet (British edition), 2020-02, Vol.395 (10222), p.427-440

2020

Volltextzugriff (PDF)

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments

Journal of the American Academy of Dermatology, 2021-05, Vol.84 (5), p.1254-1268

2021

Volltextzugriff (PDF)

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study

Rheumatology (Oxford, England), 2017-11, Vol.56 (11), p.1993-2003

2017

Volltextzugriff (PDF)

Targeting Notch‐Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis

Journal of bone and mineral research, 2017-07, Vol.32 (7), p.1469-1480

2017

Volltextzugriff (PDF)

Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis

Nature reviews. Rheumatology, 2018-02, Vol.14 (2), p.94-106

2018

Volltextzugriff (PDF)

1 – 25 von 394

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(340)
Mit Volltextzugriff
(275)

Publikationsform

Artikel
(381)
Buchkapitel
(10)
Bücher
(2)
Berichte
(1)

Sprache

Englisch
(394)

Erscheinungsjahr

n.n

Thema

Science & Technology
(248)
Life Sciences & Biomedicine
(238)
Humans
(209)
Rheumatology
(192)
Psoriatic Arthritis
(153)
Psoriasis
(113)
Arthritis
(66)
Animals
(63)
Arthritis, Psoriatic - Drug Therapy
(60)
Female
(60)
Male
(60)
Treatment Outcome
(53)
Dermatology
(48)
Rheumatoid Arthritis
(48)
Adult
(46)
Middle Aged
(45)
Biological And Medical Sciences
(44)
Antirheumatic Agents - Therapeutic Use
(43)
Medical Sciences
(42)
Patients
(42)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Psoriatic Arthritis

Axial spondyloarthritis: new advances in diagnosis and management

Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL)

Etanercept and Methotrexate as Monotherapy or in Combination for Psoriatic Arthritis: Primary Results From a Randomized, Controlled Phase III Trial

In Memoriam: Evan Calkins, MD, 1920–2020

Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial

Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis

Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey

Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3)

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial

DC-STAMP: A Key Regulator in Osteoclast Differentiation

Altered Bone Remodeling in Psoriatic Disease: New Insights and Future Directions

Influence of Axial Involvement on Clinical Characteristics of Psoriatic Arthritis: Analysis from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

New therapies for psoriasis and psoriatic arthritis

Targeting the interleukin-23/17 axis in axial spondyloarthritis

Etiology and Pathogenesis of Psoriatic Arthritis

Overview of the Grant Writing Workshop From the GRAPPA 2020 Annual Meeting

High-throughput micro-CT analysis identifies sex-dependent biomarkers of erosive arthritis in TNF-Tg mice and differential response to anti-TNF therapy

Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

National Psoriasis Foundation COVID-19 Task Force guidance for management of psoriatic disease during the pandemic: Version 2—Advances in psoriatic disease management, COVID-19 vaccines, and COVID-19 treatments

Secukinumab sustains improvement in signs and symptoms of psoriatic arthritis: 2 year results from the phase 3 FUTURE 2 study

Targeting Notch‐Activated M1 Macrophages Attenuates Joint Tissue Damage in a Mouse Model of Inflammatory Arthritis

Targeting lymphatic function as a novel therapeutic intervention for rheumatoid arthritis

Suchergebnisse filtern